The Hong Kong Chamber of Commerce in Sweden (HKCCSE) is proud to conclude a highly successful Swedish Life Science Delegation to Hong Kong (10–12 December 2025) — three intensive days of dialogue, discovery, and connection across the Hong Kong–Sweden life science ecosystems.
The delegation brought together innovative Nordic life science companies and ecosystem leaders to engage with Hong Kong’s dynamic environment spanning policy, regulation, research, innovation platforms, clinical settings, and capital markets. The visit once again demonstrated Hong Kong’s unique strength as a gateway to the Greater Bay Area (GBA) and Asia — where science, capital, and global market access converge.
Across the programme, delegates participated in high-quality exchanges that resulted in new institutional relationships, concrete collaboration discussions, and clearer pathways for partnerships, pilots, and market entry in Hong Kong and the GBA.
We would like to express our sincere appreciation to our hosting and supporting partners for their openness, professionalism, and strong engagement:
Hong Kong Biotechnology Organization HKBIO
Office for Attracting Strategic Enterprises
Invest Hong Kong
HKSTP – Hong Kong Science and Technology Parks Corporation (HKSTP)
HSITP Hong Kong-Shenzhen Innovation and Technology Park
City University of Hong Kong
HK Tech 300
HKUMed – The University of Hong Kong
Hong Kong Exchanges and Clearing Limited (HKEX)
YNBY International Limited (Stock code 30.HK)
AstraZeneca
Consulate General of Sweden in Hong Kong and Macau
Swedish Chamber of Commerce in Hong Kong
A special thank you to Lucy Robertshaw for excellent coordination.
Most importantly, we would like to thank the five Nordic participants for their strong engagement, openness, and commitment to building international collaboration:
NextCell Pharma AB
SampleFacts
Veltio Pharma AB
UIC – Uppsala Innovation Centre
Tara Heitner
From HKCCSE’s perspective, this delegation marks a key milestone in re-activating and accelerating Sweden–Hong Kong cooperation in life science, biotech, medtech, and innovation. The momentum is strong, the interest is real — and the next phase now begins.
We look forward to continuing the dialogue and turning these connections into long-term partnerships and tangible outcomes.